GlassScriptPhysician profile
Ressia Y Lee
NPI 1780782938
$760.53
in general payments reported to CMS, 2019-2025
12 companies · $70.56 in 2025
The $70.56 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $78.58 · 2021: $155 · 2022: $22.24 · 2023: $65.19 · 2024: $50.54 · 2025: $70.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $186.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $265.05 | 2019-2021 | |
| Glaxosmithkline, LLC. | $142.04 | 2019-2023 | Bexsero, Rotarix, Pediarix |
| Boston Scientific Corporation | $85.18 | 2019-2021 | |
| Sanofi Pasteur INC. | $45.62 | 2024-2025 | |
| Cranial Technologies, INC | $38.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.15 | 2019-2021 | |
| Sobi, INC | $32.07 | 2021 | |
| Alk-Abello, INC | $27.78 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $25.74 | 2024 | Ycanth |
| Kaleo, INC. | $22.59 | 2019 | |
| Novo Nordisk INC | $21.96 | 2025 | Ozempic, Rybelsus |
| Ironshore Pharmaceuticals INC. | $16.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ressia Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.